Synergistic increase in the sensitivity of osteosarcoma cells to thermochemotherapy with combination of paclitaxel and etoposide

Huang,T.; Gong,W. H.; Li,X. C.; Zou,C.  P.; Jiang,G. J.; Li,X. H.; Feng,D. P.

doi:10.3892/mmr.2012.1058

Synergistic increase in the sensitivity of osteosarcoma cells to thermochemotherapy with combination of paclitaxel and etoposide

Authors:
- T. Huang
- W. H. Gong
- X. C. Li
- C. P. Zou
- G. J. Jiang
- X. H. Li
- D. P. Feng
View Affiliations

Affiliations: Department of Orthopedics, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Published online on: September 3, 2012 https://doi.org/10.3892/mmr.2012.1058
Pages: 1013-1017

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is a malignant bone tumor which is found most commonly in adolescents and young adults. Local perfusion thermochemotherapy has long been proposed as an alternative strategy for the treatment of osteosarcoma. As a standard anticancer drug, paclitaxel plays a significant role in the treatment of a number of tumors; however, little is known concerning its ability to promote thermochemotherapy. The aim of this study was to evaluate the cytotoxic effects of a combination of paclitaxel and etoposide on an osteosarcoma cell line in the presence of hyperthermia and to investigate the related mechanism. Our study indicated that 1 h after the application of a combination of 10 µg/ml paclitaxel and 5 µg/ml etoposide to OS732 cells at 43˚C, the survival rate of the cells was 14.52% which was significantly lower than when either 10 µg/ml paclitaxel (45.83%) or 5 µg/ml etoposide (43.31%) was applied alone (P<0.01). Moreover, changes in cellular morphology and apoptotic rates indicated that the apoptosis-inducing effect of the combination was much stronger than that of either drug applied individually. Fas expression levels in the OS732 cells were increased by the combination of paclitaxel and etoposide in the presence of hyperthermia. Therefore, paclitaxel enhances the thermochemotherapy of the osteosarcoma cell line and this is primarily accomplished by the upregulation of Fas expression and the induction of apoptosis.

View Figures

View References

1	Bacci G, Balladelli A, Palmerini E, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremities in preadolescent patients: the Rizzoli Institute experience. J Pediatr Hematol Oncol. 30:908–912. 2008.
2	Bacci G, Rocca M, Salone M, et al: High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary andmetastatic lesions. J Surg Oncol. 98:415–420. 2008.
3	Franke M, Hardes J, Helmke K, et al: Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer. 56:771–776. 2011.
4	Andreou D, Bielack SS, Carrle D, et al: The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Ann Oncol. 22:1228–1235. 2011.
5	Routt SM, Zhu J, Zaleski JM and Dynlacht JR: Potentiation of metalloenediyne cytotoxicity by hyperthermia. Int J Hyperthermia. 27:435–444. 2011.
6	Streckfus CF, Brown RE and Bull JM: Proteomics, morphoproteomics, saliva and breast cancer: an emerging approach to guide the delivery of individualised thermal therapy, thermochemotherapy and monitor therapy response. Int J Hyperthermia. 26:649–661. 2010.
7	Trieb K, Blahovec H and Kubista B: Effects of hyperthermia on heat shock protein expression, alkaline phosphatase activity and proliferation in human osteosarcoma cells. Cell Biochem Funct. 25:669–672. 2007.
8	Fan QY, Ma BA, Zhou Y, et al: Bone tumors of the extremities or pelvis treated by microwave-induced hyperthermia. Clin Orthop Relat Res. 406:165–175. 2003.
9	Shido Y, Nishida Y, Suzuki Y, et al: Targeted hyperthermia using magnetite cationic liposomes and an alternating magnetic field in a mouse osteosarcoma model. J Bone Joint Surg Br. 92:580–585. 2010.
10	Vujaskovic Z, Kim DW, Jones E, et al: A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia. 26:514–521. 2010.
11	Tang Y and McGoron AJ: Combined effects of laser-ICG photothermotherapy and doxorubicin chemotherapy on ovarian cancer cells. J Photochem Photobiol B. 97:138–144. 2009.
12	Fiorillo A, DeRosa G, Giugliano F, et al: Efficacy of pegylated lyposomal anthracyclines and of intra-arterial carboplatin and doxorubicin combined with local hyperthermia in a case of malignant endovascular papillary angioendothelioma. Curr Drug Deliv. 6:58–61. 2009.
13	Liu B, Yang M, Li X, et al: Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer. J Pharm Sci. 97:3170–3181. 2008.
14	Michalakis J, Georgatos SD, de Bree E, et al: Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro. Ann Surg Oncol. 14:1220–1228. 2007.PubMed/NCBI
15	Zoul Z, Filip S, Melichar B, et al: Weekly paclitaxel combined with local hyperthermia in the therapy of breast cancer locally recurrent after mastectomy - a pilot experience. Onkologie. 27:385–388. 2004.
16	Mohamed F, Marchettini P, Stuart OA, et al: Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 10:463–468. 2003.
17	de Bree E, Theodoropoulos PA, Rosing H, et al: Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside (Review). Cancer Treat Rev. 32:471–482. 2006.
18	de Bree E, Rosing H, Michalakis J, et al: Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination (Review). Eur J Surg Oncol. 32:666–670. 2006.
19	Miyata S, Takemura G, Kosai K, et al: Anti-Fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis. Am J Pathol. 176:687–698. 2010.
20	Kim HS, Lee YS and Kim DK: Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death. Pharmacology. 84:300–309. 2009.
21	Li S, Zhou Y, Dong Y and Ip C: Doxorubicin and selenium cooperatively induce Fas signaling in the absence of Fas/Fas ligand interaction. Anticancer Res. 27:3075–3082. 2007.
22	Drago-Ferrante R, Santulli A, Di Fiore R, et al: Low doses of paclitaxel potently induce apoptosis in human retinoblastoma Y79 cells by up-regulating E2F1. Int J Oncol. 33:677–687. 2008.PubMed/NCBI
23	Pires NM, Eefting D, de Vries MR, et al: Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. Heart. 93:922–927. 2007.
24	Stumm S, Meyer A, Lindner M, et al: Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor. Oncology. 66:101–111. 2004.
25	Huisman C, Ferreira CG, Bröker LE, et al: Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res. 8:596–606. 2002.
26	Wang X, Gao XH, Li X, et al: Local hyperthermia induces apoptosis of keratinocytes in both normal skin and condyloma acuminata via different pathways. Apoptosis. 14:721–728. 2009.
27	Yu DY, Matsuya Y, Zhao QL, et al: Enhancement of hyperthermia-induced apoptosis by a new synthesized class of furan-fused tetracyclic compounds. Apoptosis. 12:1523–1532. 2007.
28	Ohguri T, Imada H, Narisada H, et al: Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results. Int J Hyperthermia. 25:160–167. 2009.
29	Hulshof MC, Van Haaren PM, Van Lanschot JJ, et al: Preoperative chemoradiation combined with regional hyperthermia for patients with resectable esophageal cancer. Int J Hyperthermia. 25:79–85. 2009.